Tracers / [18F]Fluciclatide

[18F]Fluciclatide

Also written as [18F]AH111585; [18F]Fluciclatide; [F-18]AH111585; [F-18]Fluciclatide; AH111585; F-18 AH111585; F-18 Fluciclatide
Radionuclide
F-18 t½ 109.7 min
Modality
PET
Production route
Cyclotron liquid target
Stage
Research
Syntheses indexed
0

What it is

Compound class
Peptide (RGD)
Target / mechanism
Integrin alpha-v beta-3 (RGD peptide); marker of angiogenesis PMID 19719118 / DOI 10.1021/bc900167c
Clinical application
Imaging of angiogenesis / integrin alpha-v beta-3 expression; response to antiangiogenic therapy PMID 26383153 / DOI 10.2967/jnumed.115.158253
Theranostic pair

Regulatory status

FDA
No Drugs@FDA / openFDA drug registry — no approved application found; search: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process&searchTerm=fluciclatide
EMA (centralised)
Other approvals
Brand names

Clinical use

Typical injected activity
Target dose ~230 MBq (229 +/- 12 MBq); other studies up to 370 MBq PMID 27927700 / DOI 10.1136/heartjnl-2016-310115; PMID 26383153 / DOI 10.2967/jnumed.115.158253
Uptake time
Static imaging ~40 min post-injection (dynamic/patient scans acquired 40-90 min p.i.) PMID 27927700 / DOI 10.1136/heartjnl-2016-310115; PMID 26383153 / DOI 10.2967/jnumed.115.158253

Reported in the literature. Not a dosing recommendation.

Published syntheses

No synthesis has been parsed for this agent yet.

Precursor

Common precursor
Amino-oxy-functionalised cyclic-RGD peptide precursor AH111695, coupled with 4-[18F]fluorobenzaldehyde at pH 3.5 PMID 27927700 / DOI 10.1136/heartjnl-2016-310115
Suppliers seen in the literature
Typical final purification
SPE

Need this precursor?We can point you to suppliers for [18F]Fluciclatide, or handle the enquiry for you.

Get in touch

Quality control Preliminary — inferred from compound class

Ph. Eur. monograph
USP monograph
AppearancepHRCP HPLCRCP TLCHPLC UVRadionuclidic (HPGe)Half-lifeActivityEndotoxins (LAL)SterilityFilter integrity
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); organic-phase radiosynthesis assumed from isotope/compound class, no synthesis data confirming it -> GC residual solvents (preliminary); conventional nucleophilic 18F-fluorination assumed from isotope/compound class, no synthesis data confirming K222 use -> Kryptofix test (preliminary)

Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived

Setting up quality control?We can help you scope the equipment needed to release [18F]Fluciclatide.

Get in touch